Liquid Biopsy
News and reporting on cell-free DNA testing.
Foundation Medicine Test Approved by FDA as CDx for Itovebi in Breast Cancer Patients
The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Myriad Genetics Enters Collaborations to Study MRD, Announces Preliminary Q3 Revenue Estimates
The company is studying the use of its Precise MRD test in the breast cancer setting. It also said it estimates between $210 million and $212 million in Q3 revenue.
Aitiologic Developing Liquid Biopsy Assay for Tissue-of-Origin Analysis, Early Disease Detection
Premium
The Austrian startup's assay and software, which are early in R&D, promise to profile both the genetic and epigenetic signatures of cell-free DNA from blood samples.
Researchers Stress Specificity of Grail Multi-Cancer Detection Test in Response to Study Criticism
Premium
The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.
Oncocyte Nets $10.2M in Private Placement, Notes New Customers for Transplant Test
The company intends to use the funds for general corporate purposes as it seeks to gain customers and regulatory support for its GraftAssure transplant rejection test.